Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A retrospective, non-interventional cohort study was used to address the study objectives. This study aimed to provide a better understanding of real-world healthcare resource utilization (HRU) and healthcare reimbursement costs associated with chimeric antigen receptor modified T cell (CAR-T) therapy among patients with DLBCL.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CAR-T IP | Chimeric antigen receptor modified T cells inpatient cohort | ||
| CAR-T OP | Chimeric antigen receptor modified T cells outpatient cohort | ||
| CAR-T Overall | Chimeric antigen receptor modified T cells overall cohort | ||
| allo-HSCT | Allogeneic hematopoietic stem cell transplant cohort |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Number of hospital admissions in the CAR-T IP and CAR-T OP cohorts | Up to approximately 10 months | |
| Number of inpatient (IP) days in the CAR-T IP and CAR-T OP cohorts | Up to approximately 10 months | |
| Number of intensive care unit (ICU) stays in the CAR-T IP and CAR-T OP cohorts | Up to approximately 10 months | |
| Number of ICU days in the CAR-T IP and CAR-T OP cohorts | Up to approximately 10 months | |
| Number of emergency room (ER) visits in the CAR-T IP and CAR-T OP cohorts | Up to approximately 10 months | |
| Number of outpatient (OP) visits in the CAR-T IP and CAR-T OP cohorts | Up to approximately 10 months | |
| Percentage of patients in the CAR-T IP and CAR-T OP cohorts with any IP admission | Up to approximately 10 months | |
| Percentage of patients in the CAR-T IP and CAR-T OP cohorts with ER visits | Up to approximately 10 months | |
| Percentage of patients in the CAR-T IP and CAR-T OP cohorts with OP services | Up to approximately 10 months | |
| Total pre-infusion healthcare reimbursement costs in the CAR-T IP and CAR-T OP cohorts |
| Measure | Description | Time Frame |
|---|---|---|
| Cumulative percentage of patients admitted in the hospital during the first month after CAR-T OP infusion | Up to approximately 10 months | |
| Percentage of patients hospitalized each day during the first month after CAR-T infusion among the CAR-T IP and OP cohorts |
Not provided
Inclusion Criteria:
CAR-T cohort:
Allo-HSCT cohort:
Exclusion criteria:
• Patients had a medical claim associated with a clinical trial (ICD-9 CM code V70.7; ICD-10 CM code Z00.6) during one month before and after the index date.
Not provided
Not provided
Not provided
This was a retrospective, noninterventional cohort study.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis | East Hanover | New Jersey | 07936 | United States |
Not provided
| ID | Term |
|---|---|
| D016403 | Lymphoma, Large B-Cell, Diffuse |
| ID | Term |
|---|---|
| D016393 | Lymphoma, B-Cell |
| D008228 | Lymphoma, Non-Hodgkin |
| D008223 | Lymphoma |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
Not provided
Not provided
Not provided
| Up to approximately 10 months |
| Total CAR-T infusion-related healthcare reimbursement costs in the CAR-T IP and CAR-T OP cohorts | Up to approximately 10 months |
| Total post-infusion healthcare reimbursement costs in the CAR-T IP and CAR-T OP cohorts | Up to approximately 10 months |
| Up to approximately 10 months |
| Main cause of IP admission/re-admission among the CAR-T IP and OP cohorts, up to three months following infusion | Up to approximately 10 months |
| Percentage of patients with AEs | Up to approximately 10 months |
| Healthcare reimbursement costs per AE event | Up to approximately 10 months |
| Number of IP admissions in the overall CAR-T and allo-HSCT cohorts | Up to approximately 10 months |
| Number of IP days in the overall CAR-T and allo-HSCT cohorts | Up to approximately 10 months |
| Number of OP visits in the overall CAR-T and allo-HSCT cohorts | Up to approximately 10 months |
| Number of ER visits in the overall CAR-T and allo-HSCT cohorts | Up to approximately 10 months |
| Total healthcare reimbursement costs in the overall CAR-T and allo-HSCT cohorts | Up to approximately 10 months |
| Main cause of IP admission/re-admission among the CAR-T IP and OP cohorts | Up to approximately 10 months |
| Number of intensive care unit (ICU) stays in the overall CAR-T and allo-HSCT cohorts | Up to approximately 10 months |
| Number of ICU days in the overall CAR-T and allo-HSCT cohorts | Up to approximately 10 months |
| D009369 |
| Neoplasms |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |